Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

Presentation TCT 2016

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Presenter: Eberhard Grube, James B. Hermiller Jr., Jeffrey J. Popma

November 01, 2016

‘Promising’ SENTINEL Cerebral Protection in TAVR Collects Debris but Misses Primary Endpoint

News Conference News TCT 2016

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

Shelley Wood

November 01, 2016

Presentation TCT 2016

TCT 37: Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at High Risk for Surgery: One-Year Results From the Evolut R US Pivotal Study

Presenter: Lutz Buellesfeld, Raj Makkar, Jeffrey J. Popma

October 31, 2016

Presentation TCT 2016

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Presenter: Michael Argenziano, Alec S. Vahanian, Patrick T. O'Gara

October 31, 2016

Presentation TCT 2016

Role of Papillary Muscle Relocation in Ischemic Mitral Valve Regurgitation

Presenter: Michael J. Mack, Francesco Maisano, Marco Moscarelli

October 30, 2016

Presentation TCT 2016

How Good Can Surgical Outcomes Be in Secondary MR?

Presenter: Michael J. Mack, Francesco Maisano, Michael Argenziano

October 30, 2016

Presentation TCT 2016

Applying Lessons From the CTSN to Clinical Practice

Presenter: Michael J. Mack, Francesco Maisano

October 30, 2016

Presentation TCT 2016

Minimally Invasive and Robotic Repair for Primary MR: Less Invasive With Great Outcomes?

Presenter: Michael J. Mack, Francesco Maisano, Robert L. Smith

October 30, 2016

Presentation TCT 2016

Surgical Outcomes in Primary MR: Results From Expert Surgeons vs Real Life Surgeons

Presenter: Michael J. Mack, Francesco Maisano, Patrick M. McCarthy

October 30, 2016

Presentation TCT 2016

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Jeffrey J. Popma

October 30, 2016

News Daily News

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

L.A. McKeown

October 27, 2016

News Daily News

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

Caitlin E. Cox

October 04, 2016

News Daily News

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

Caitlin E. Cox

October 04, 2016

News Daily News

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

Shelley Wood

September 29, 2016

News Daily News

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Shelley Wood

September 29, 2016

News Conference News PCR London Valves 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Conference News PCR London Valves 2016

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

Shelley Wood

September 19, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

Advertisement

Evolut R and 2.0: Design Features, Special Attributes, and Clinical Trial Program

Sentinel Cerebral Protection Device in TAVR ‘Promising’ but Trial Misses Primary Endpoint

TCT 37: Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis at High Risk for Surgery: One-Year Results From the Evolut R US Pivotal Study

Rationale for and Design of SAPIEN LOW RISK and EVOLUTE LOW RISK

Role of Papillary Muscle Relocation in Ischemic Mitral Valve Regurgitation

How Good Can Surgical Outcomes Be in Secondary MR?

Applying Lessons From the CTSN to Clinical Practice

Minimally Invasive and Robotic Repair for Primary MR: Less Invasive With Great Outcomes?

Surgical Outcomes in Primary MR: Results From Expert Surgeons vs Real Life Surgeons

Low-Risk Studies: Design and Updates III - The Evolut R Low-Risk Trial

FDA Approves 34-mm TAVR Valve for Patients With Larger Anatomy

Registro FRANCE 2: 3 Años Después de una TAVR, el Rendimiento de la Válvula se Mantiene y casi Toda la Mortalidad es No Cardíaca

At 3 Years Post-TAVR, Valve Performance Holds Steady and Most Mortality Is Noncardiac: FRANCE 2 Registry

某些患者 TAVR 后认知改善，但也有些下降，导致很难有统一指南

La Cognición Post-TAVR Mejora en Algunos Pacientes y Desciende en Otros y son Pocas las Señales Orientativas

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content